<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39350163</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.</ArticleTitle><Pagination><StartPage>239</StartPage><MedlinePgn>239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02475-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P&lt;0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P &lt;0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bohoněk</LastName><ForeName>Miloš</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Máca</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology and Pathological Physiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagan</LastName><ForeName>Jiří</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Řezáč</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The 7th Field Hospital of the Army of the Czech Republic, Hradec Králové, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fridrich</LastName><ForeName>Viktor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burantová</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutáč</LastName><ForeName>Dominik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vabroušek</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubů</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Science and Research, University Hospital Bulovka Prague, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrdle</LastName><ForeName>Aleš</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, České Budejovice Hospital, České Budějovice, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Social Sciences, University of South Bohemia, České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volfová</LastName><ForeName>Kateřina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, České Budejovice Hospital, České Budějovice, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blahutová</LastName><ForeName>Šárka</ForeName><Initials>Š</Initials><AffiliationInfo><Affiliation>Institute of Laboratory Hematology and Transfusion Medicine, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rychlík</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonášková</LastName><ForeName>Kateřina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majerčin</LastName><ForeName>Radek</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Resuscitation, Regional Hospital Jičín, Jičín, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Králová</LastName><ForeName>Radka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Resuscitation, Regional Hospital Jičín, Jičín, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Štěpánek</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Resuscitation, Regional Hospital Náchod, Náchod, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holub</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic. michal.holub@uvn.cz.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha, U Vojenské nemocnice 1200, Praha 6, 169 06, Czech Republic. michal.holub@uvn.cz.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MO1012</GrantID><Agency>Ministerstvo Obrany České Republiky</Agency><Country /></Grant><Grant><GrantID>MO1012</GrantID><Agency>Ministerstvo Obrany České Republiky</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093522" MajorTopicYN="Y">COVID-19 Serotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018153" MajorTopicYN="N" Type="Geographic">Czech Republic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Convalescent plasma</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350163</ArticleId><ArticleId IdType="pmc">PMC11443855</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02475-y</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02475-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol. 2004;11:665–8. 10.1128/CDLI.11.4.665-668.2004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC440610</ArticleId><ArticleId IdType="pubmed">15242938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–6. 10.1007/s10096-004-1271-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088355</ArticleId><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56:919–22. 10.1093/jac/dki346</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110092</ArticleId><ArticleId IdType="pubmed">16183666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77:147–50. 10.1002/jmv.20431</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167078</ArticleId><ArticleId IdType="pubmed">16121363</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using Convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22:1554–61. 10.3201/eid2209.151164</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994343</ArticleId><ArticleId IdType="pubmed">27532807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. 10.1093/infdis/jiu396</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264590</ArticleId><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23:39–44. 10.1016/j.tracli.2015.12.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110444</ArticleId><ArticleId IdType="pubmed">26775794</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695–03. 10.1038/nrmicro974</Citation><ArticleIdList><ArticleId IdType="pubmed">15372080</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145:599–09. 10.7326/0003-4819-145-8-200610170-00139</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–56. 10.1093/cid/ciq106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7531589</ArticleId><ArticleId IdType="pubmed">21248066</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks, WHO Interim Guidance for National Health Authorities and Blood Transfusion Services, Version 1.0. September 2014, WHO/HIS/SDS/2014.8. https://apps.who.int/iris/handle/10665/135591; 2014 [accessed 3 April 2024].</Citation></Reference><Reference><Citation>Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect. 2017;74(3):302–9. 10.1016/j.jinf.2016.11.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112610</ArticleId><ArticleId IdType="pubmed">27867062</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES et al. Effect of Convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-Month experience. Effect of Convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-Month experience | medRxiv; 2020 [accessed 12 April 2024].</Citation></Reference><Reference><Citation>Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384:610–8. 10.1056/NEJMoa2033700</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>An EU. programme of COVID-19 convalescent plasma collection and transfusion. https://health.ec.europa.eu/document/download/04a77c82-906e-4840-bc35-0faaccd33f02_en; 2020 [accessed 12 April 2024].</Citation></Reference><Reference><Citation>Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A Randomized Trial of Convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–29. 10.1056/NEJMoa2031304</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722692</ArticleId><ArticleId IdType="pubmed">33232588</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [published correction appears in BMJ. 2020;371:m4232]. BMJ 2020;371:m3939. 10.1136/bmj.m3939</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–59. 10.1016/S0140-6736(21)00897-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohoněk M, Bělochová J, Čermáková Z, Dušková D, Gašová Z, Galuszková D, et al. Výroba a použití rekonvalescentní plazmy anti-SARS-CoV-2 v ČR: stručná informace. Trans Hematol dnes. 2021;27(2):189–90.</Citation></Reference><Reference><Citation>FDA Issues Emergency Use Authorization for Convalescent. Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment; 2020 [accessed 12 April 2024].</Citation></Reference><Reference><Citation>Černý V, Bohoněk M, Dlouhý P, Vašáková M. Mezioborové stanovisko k podávání rekonvalescentní plazmy u pacientů s COVID-19, ev. č. ČSARIM: 18/2021, 2.3.2021. https://www.csarim.cz/getmedia/0d4a80ec-41de-459b-aa2c-1f6a2f1042a5/2021_PP_18_CSARIM_STL_SIL_CPFS_Rekonv_plazma_final_020321.pdf.aspx; 2020 [accessed 12 April 2024].</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–26. 10.1056/NEJMoa2007764</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188185</ArticleId><ArticleId IdType="pubmed">16129869</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohoněk M, Řezáč D, Kutáč D, Vabroušek P, Kubů J, Jakub T, et al. Report on the program of the use of convalescent plasma in the treatment of patients with COVID-19 in the Czech Republic and the results of the national multicentre study RESCOVID-19. Trans Hematol dnes. 2023;29:193–9.</Citation></Reference><Reference><Citation>Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–70. 10.1001/jama.2020.10044</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136:759–62. 10.1182/blood.2020006964</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414587</ArticleId><ArticleId IdType="pubmed">32559767</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and Meta-analysis. JAMA Netw Open. 2023;6:e2250647. 10.1001/jamanetworkopen.2022.50647</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857047</ArticleId><ArticleId IdType="pubmed">36633846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VCC, Edwards KM et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2022 Sep 5:ciac724. 10.1093/cid/ciac724</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA announces Evusheld is not currently authorized for emergency use in the U.S. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:~:text=Update%20%5B1%2F26%2F2023,than%20or%20equal%20to%2090%2; 2023 [accessed 12 April 2024].</Citation></Reference><Reference><Citation>Martinuka O, von Cube M, Wolkewitz M. Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness. Clin Microbiol Infect. 2021;27:949–57. 10.1016/j.cmi.2021.03.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015394</ArticleId><ArticleId IdType="pubmed">33813117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>